Insect-repellant market contested by 3 domestic pharmaceutical firms

Published: 2008-06-24 06:32:00

Updated: 2008-06-24 06:32:00

Business sources say that the domestic household insect-repellant market valued at 7.0 billion won has emerged as an arena of tripartite competition among three pharmaceutical manufactures.

Hyundai Pharm says that market share of Bermuly-S (diphenhydramine HCl) accounts for 41 percent thanks ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK